Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Arsenal Bio

Main focus: Next-generation autologous T cell therapies

Company stage: Commercial

Diseases (gene editing): Cancer

Genome editing tool: CRISPR

Funding stage: Private

Location: South San Francisco, CA, USA

Website: https://www.arsenalbio.com/

Gene editing partnerships: Bristol Myers Squibb

Arsenal Bio develops multiple proprietary technology platforms, CellFoundry™, PrimeR™ and CARchitecture™ which together with the CRISPR technology form the foundation for its next-generation therapies. While the company has yet to disclose its lead programmes, it has announced a collaboration with Bristol Myers Squibb (BMS) where the two companies will discover and develop T cell therapies for the treatment of solid tumours.

ArsenalBio

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

CMN Weekly (21 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 21, 2025

Some of the best links we picked up around the internet

Bahrain Reports First Administration of CASGEVY in...

Feb. 19, 2025

The Bahrain Oncology Centre announced a major milestone on Sunday with the successful administration of CASGEVY - the world's only approved therapy...

CRISPR–Csm enables single-molecule RNA imaging in...

CMN Briefs

Feb. 18, 2025

A new technique developed by Jennifer Doudna and colleagues at the University of California, Berkeley, achieves single-molecule resolution imaging of...

CRISPR screen links BAF mutation to premature...

CMN Briefs

Feb. 17, 2025

A genome-wide CRISPR screen in fibroblasts from patients with Néstor-Guillermo Progeria Syndrome (NGPS) identified 43 genes that mitigate multiple...

CMN Weekly (14 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 14, 2025

Some of the best links we picked up around the internet

FDA Grants Dual Designations to Arbor's Gene...

CMN Clinical

Feb. 12, 2025

The FDA has granted orphan drug and rare pediatric disease designations to Arbor Biotechnologies' ABO-101, a gene-editing therapeutic candidate for...